Journal of the National Comprehensive Cancer Network · 2019 · 1K citations · 31 references
MedicineOncologyCancer ImmunologyImmunotherapyThoracic OncologyCancer ImmunotherapyCombination ImmunotherapyImmunotherapy For Thoracic MalignanciesLung CancerSystemic Therapy For Thoracic MalignanciesNon-small Cell Lung Cancer Adjuvant TherapyNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentStratification
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."
31
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text
Medicine, Oncology, Pharmacology +16